YEONG-SHIAU PUFujimoto H.Kakizoe T.Myers R.2021-02-022021-02-0220050368-2811https://www.scopus.com/inward/record.uri?eid=2-s2.0-30444440162&doi=10.1093%2fjjco%2fhyi180&partnerID=40&md5=0a0447232087298e9d06d4f6a2712107https://scholars.lib.ntu.edu.tw/handle/123456789/544501[SDGs]SDG3androgen; androgen receptor; antiandrogen; antineoplastic agent; aromatase; bicalutamide; cancer vaccine; daidzein; docetaxel; equol; estramustine; finasteride; ganciclovir; gene product; genistein; gonadorelin agonist; interleukin 12; iodine 125; isoflavone derivative; mitoxantrone; palladium 103; peptide derivative; placebo; prednisolone; prednisone; prostate specific antigen; radioisotope; thymidine kinase; tumor antigen; unindexed drug; cancer epidemiology; cancer research; cancer screening; cancer staging; cancer survival; clinical trial; conference paper; diagnostic imaging; diet therapy; digital rectal examination; gene mutation; histopathology; human; male; medical society; multimodality cancer therapy; nonhuman; prostate biopsy; prostate cancer; prostatectomy; tea; viral gene delivery system; Biopsy; Gene Therapy; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic NeoplasmsConference Paper10.1093/jjco/hyi180162756752-s2.0-30444440162